Tetrahydrocannabivarin

DB11755InvestigationalSmall molecule

Tetrahydrocannabivarin (THCV) is a propyl analogue of tetrahydrocannabinol (Δ9-THC), one of the primary pharmacological components of Medical Cannabis. Δ9-THC is currently available in several synthetic forms, including Dronabinol, while purified... As a major phytocannabinoid, however, THCV is accessible within Medical Cannabis along with other identified cannabinoids including Cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), cannabivarin (CBV), and Cannabidivarin (CBDV).

Mechanism: Pharmacologically active on Cannabinoid receptor 1, G protein-coupled receptor 55, and 5-hydroxytryptamine receptor 1A
Curator reviewed
Primary indication: THCV does not currently have any FDA, Health Canada, or EMA approved indications.Curator reviewed
Formula / weight: C₁₉H₂₆O₂ · 286.415 g/mol (avg)
Also known as: THCV
Code names: GWP-42004 · O-4394

Resolves to

Compound

UNIII5YE3I47D8CAS31262-37-0ChEMBLCHEMBL2387541PubChem93147

Structure

InChIKeyZROLHBHDLIHEMS-HUUCEWRRSA-NSMILESCCCC1=CC(O)=C2[C@@H]3C=C(C)CC[C@H]3C(C)(C)OC2=C1

Targets

P21554CNR1Q9Y2T6GPR55P08908HTR1AQ9Y5S1TRPV2Q7Z2W7TRPM8O75762TRPA1Q8NET8TRPV3P34972CNR2

What you can answer from here — as of January 29, 2025

8Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1,068Drug interactionsStructured to mechanism, not free text

5Clinical trialsPhase, status and sponsor resolved per trial

21+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tetrahydrocannabivarin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account